Form 4: Beam Therapeutics CLO Granted 40,000 Stock Options

Beam Therapeutics' Chief Legal Officer, Christine Bellon, was granted 40,000 stock options with an exercise price of $27.62, vesting over 48 months.

Summary

• Christine Bellon, Chief Legal Officer of Beam Therapeutics Inc. (BEAM), was granted 40,000 stock options.
• The options have an exercise price of $27.62 per share.
• The grant date for these options is January 31, 2026.
• The options vest in equal monthly installments over 48 months following the grant date.
• Vesting is contingent upon Ms. Bellon's continued service with Beam Therapeutics Inc. through each vesting date.
• The expiration date for these stock options is January 31, 2036.
• Following this transaction, Ms. Bellon beneficially owns 40,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It represents a routine executive compensation action, aligning management incentives with shareholder value, but does not indicate any new operational or financial performance.

Positives

• The grant of stock options aligns the Chief Legal Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• Equity compensation is a standard practice for executive retention and motivation in the biotechnology sector.

Future Outlook

The stock options are subject to a 48-month vesting schedule, indicating an expectation of continued service from the Chief Legal Officer through January 2030 to fully realize the equity grant.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options, are a common component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to attract, retain, and motivate key personnel by linking their financial incentives to the company's long-term stock performance.

Comparison to Industry Standards

• Equity compensation, including stock options with multi-year vesting schedules, is a standard practice across the biotechnology sector for executive and key employee retention, comparable to practices at companies like CRISPR Therapeutics or Editas Medicine.
• The 48-month vesting period is typical for executive equity grants, aligning with industry benchmarks for long-term incentive plans.

Stakeholder Impact

• Shareholders: The grant of options aims to align the Chief Legal Officer's long-term interests with shareholder value creation.
• Employees: This grant is part of the executive compensation structure, potentially signaling stability in key leadership roles.

Next Steps

• The Chief Legal Officer's continued service with Beam Therapeutics Inc. is required for the options to vest over the next 48 months.

Key Dates

Keywords

Beam Therapeutics, BEAM, Stock Options, Insider Transaction, Form 4, Christine Bellon, Chief Legal Officer, Equity Compensation, Executive Compensation